Back
Corporate News
At meeting held on 06 March 2025
Board of Laurus Labs approves investment of Rs 83.30 cr in KRKA Pharma
06-Mar-2025, 07:44
The Board of Laurus Labs at its meeting held on 06 March 2025 has approved investment of an amount of Rs 83.30 crore in KRKA Pharma (KRKA), a joint venture of the Company.
The Board of Laurus Labs at its meeting held on 06 March 2025 has approved investment of an amount of Rs 83.30 crore in KRKA Pharma (KRKA), a joint venture of the Company.
Further, KRKA d.d., Novo mesto, Slovenia (co-venturer) shall also invest an amount of Rs 86.70 crore in KRKA. Thereby, maintaining the existing shareholding ratio of 51:49 between KRKA d.d., Novo mesto and Laurus Labs.
The purpose of this investment is to acquire land and to meet initial cost of setting up of a manufacturing facility for production of finished products for the new markets, including the Indian market. This investment aligns with the company's strategic growth plans and long-term business objectives.
Powered by Capital Market - Live News